Please login to the form below

Not currently logged in
Email:
Password:

AbbVie to acquire cancer biotech Pharmacyclics for $21bn

Humira - AbbottComes six months after the US firm pulled out of a $54bn deal with Shire

Nikon expands into healthcare and buys retinal tech firm

Japanese camera and technology company spends big on Scotland’s Optos

SEC calls for greater disclosure from pharma

US flagClaims companies are leaving themselves open to enforcement action

Healthcare boundaries 'being erased,' says PwC

Reports claims technology is eradicating person-to-person interaction

Former Tonic directors launch Iris Life Communications

Stéphanie Bunten and Lee-Ann Cameron's new agency will be based in London's Shoreditch

NHSA awarded £2.9m to boost life and health sciences

Funding will support operations in the north of England for five years

BMS signs $975m deal for Bavarian Nordic cancer vaccine

Bristol-Myers Squibb (BMS) buildingFurthers prominent position in immuno-oncology with Prostvac

German drug cost containment system 'aids data transparency'

New study by IQWiG suggests similar rules should be rolled out across Europe

darwins medicineDoes 'trust leadership' feature in your strategy?

Pharma companies wanting to be more patient-focused will need to develop their people skills

Latest appointments

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pulsar Healthcare

Pulsar Healthcare is a forward-looking, full-service creative agency, specialising in the pharmaceutical, healthcare and medical device sectors. As such, we...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...